拉米夫定改善慢性乙型重型肝炎的疗效  

Lamivudine can improve the treatment of therapy for patients with chronic severe hepatitis B

作　　者：祐红瑞[1] 安敬军[1] 段东杰 

机构地区：[1]郑州大学第一附属医院感染科,郑州450052 [2]河南省汝州市第一人民医院内科

出　　处：《临床医学》2006年第9期5-6,共2页Clinical Medicine

摘　　要：目的观察拉米夫定治疗慢性乙型重型肝炎的疗效。方法Ⅰ组为治疗组,对20例慢性乙型重型肝炎在采用综合治疗的基础上,加用拉米夫定抗病毒治疗;Ⅱ组为对照组,32例慢性重型肝炎患者仅采用综合治疗,观察两组患者接受不同治疗方法3个月前后血清总胆红素(TB il)、凝血酶原活动度(PTA),统计学分析Ⅰ组治疗前后及两组治疗后均值差异,计算两组的有效率和病死率(有效判定标准:TB il<60μmol/L,PTA>40%),对两组有效率和病死率差异进行χ2检验。结果Ⅰ组治疗后TB il显著降低,与Ⅰ组治疗前相比较差异有统计学意义(P<0.05),与Ⅱ组治疗后相比较,差异有统计学意义(P<0.05)。Ⅰ组治疗后PTA显著升高,与Ⅰ组治疗前相比较,差异有统计学意义(P<0.05),与Ⅱ组治疗后相比较,差异有统计学意义(P<0.05)。I组有效率显著高于Ⅱ组(χ2=13.66,RR=0.03,P<0.01),I组病死率显著低于Ⅱ组(χ2=16.90,RR=10.11,P<0.01)。结论拉米夫定能改善慢性乙型重型肝炎的疗效。Objective To observe the treatment of lamivudine therapy for patients with chronic severe hepatitis B （CSHB）. Methods Group Ⅰ ,20 patients with CSHB were treated with lamivudine and general therapy ; Group Ⅱ ,40 patients with CSHB were only treated with general therapy. After 3 months, all patients were examined the TBil and PTA. The results of two groups were compared using statistical analysis. The effective rate and the fatality rate of the two groups were calculated. The results were compared using X^2 - test. Results The TBil in group Ⅰ after treatment was significantly lower than before treatment （ P 〈 0.05 ） and than group Ⅱ after treatment （ P 〈 0.05 ）. The PTA in group Ⅰ after treatment was significantly higher than before treatment（ P 〈 0.05 ） and than group Ⅱ after treatment（ P 〈 0.05 ）. The effective rate in group Ⅰ was significantly higher than group Ⅱ （x^2 = 13.66, RR =0.03, P 〈0.01 ）. The fatality rate in group I was significantly lower than in group Ⅱ （x^2 = 16.90. RR = 10.11, P 〈 0.01 ）. Conclusion Lamivudine can enhance the efficacy for patients with CSHB.

关 键 词：慢性乙型重型肝炎 拉米夫定 治疗效果 

分 类 号：R512.62[医药卫生—内科学]